W. Beau Mitchell, M.D.

Pediatric Hematology-Oncology
W. Mitchell

Board-certified in both pediatrics and hematology/oncology, Dr. Beau Mitchell is Assistant Attending Pediatrician at NewYork-Presbyterian Hospital and Clinical Assistant Professor of Pediatrics at Weill Cornell Medical College.  He also serves as Lab Head of the Laboratory of Platelet Biology at the New York Blood Center, a lab he helped establish in 2006. 
Dr. Mitchell received his B.A. at Oberlin College and his medical degree (M.D.) at Tufts University, Boston, MA.  He remained in Boston to complete his residency in pediatrics at Boston City Hospital and Boston Medical Center.  Following residency, Dr. Mitchell came to New York to complete a fellowship in pediatric hematology/oncology at Mount Sinai Medical Center.




Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Fidelis Care
  • Health First
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Freedom]
  • Oxford Health Plans [Liberty]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care [Community Plan]
  • United Health Care



  1. Mitchell WB, Li J, Murcia M, Valentin N, Newman PJ, Coller BS. Mapping early conformational changes in aIIb and b3 during biogenesis reveals a potential mechanism for aIIbb3 adopting its bent conformation. Blood, 2007 May 1:109(9):3725-3732.
  2. Peretz H, Rosenberg N, Landau M, Usher S, Nelson EJ, Mor-Cohen R, French DL, Mitchell WB, Nair SC, Chandy M, Coller BS, Srivastava A, Seligsohn U. Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3). Hum Mutat. 2006, Feb 3;27(4):359-369.
  3. Mitchell WB, Li J, French DL, Coller BS. aIIbb3 biogenesis is controlled by engagement of aIIb in the calnexin cycle via the N15-linked glycan. Blood, 2006 April 1:107(7):2713-2719.
  4. Nelson EJ, Li J, Mitchell WB, Chandy M, Srivastava A, Coller BS. Three novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb, but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi. J Thromb Haemost. 2005 Dec;3(12):2773-83.
  5. Andrea Artoni, JiHong Li, Beau Mitchell, Jian Ruan, Junichi Takagi, Tim Springer, Deborah L. French, Barry S. Coller. Integrin b3 regions controlling binding of murine mAb 7E3: Implications for the mechanism of integrin aIIbb3 activation. Proc Natl Acad Sci. 2004 Sep 7:101(36):13114-13120
  6. Deborah L. French, Steven Fruchtman, W. Beau Mitchell, Barry S. Coller. Hava Peretz Evidence for Megakaryocyte Engraftment Following Reduced Intensity Conditioning. Exp Hemat. 2004;32:877-80.
  7. WB Mitchell, J Li, F Singh, J Ruan, AD Michelson, J Bussel, BS Coller, DL French. Two novel mutations in the aIIb calcium-binding domains identify hydrophobic regions essential for aIIbb3 biogenesis. Blood, 2003 March 15;101(6):2268-2277.
  8. S Nair, J Li, WB Mitchell, D Mohanty, BS Coller, DL French. Two new beta3 integrin mutations in Indian patients with Glanzmann thrombasthenia: localization of mutations affecting cysteine residues in integrin beta3. Thromb Haemost. 2002 Sep;88(3):503-9.
  9. B Gordon, B Mitchell, K Mohtadi, E Roth, Y Tseng, F Turk. Lesions of Non-Visual Inputs Affect Plasticity, Norepinephrine Content and Acetylcholine Content of Visual Cortex. Journal Of Neurophysiology 1990, 64:1851-60.


  1. W. Beau Mitchell and James Bussel. IVIG in Hematologic Disorders, In: Alan H Lazarus and John W Semple, eds. Immunoglobulin Therapy. Bethesda, MD: AABB Press; 2010
  2. Barry S. Coller, W. Beau Mitchell, and Deborah L. French. Hereditary Qualitative Platelet Disorders. In: E. Beutler, Marshall Lichtman, Barry Coller , Thomas Kipps, Uri Seligsohn, eds. William’s Hematology; 7th edition. New York, NY: McGraw-Hill; 2006
  3. WB Mitchell and DL French, Glanzmann thrombasthenia in: The NORD Guide to Rare Disorders. Lippincott, Williams & Wilkins. Philadelphia, PA; 2003:pp 383-384

Honors and Awards

Best Figure of the Year 2005, Journal of Thrombosis and Haemostasis, 12/05
First place, Fellow’s Research Night, New York Society for the Study of Blood, 7/01
Mildred Ann Myerson Memorial Scholarship, 5/94 “given to a student who has shown a high degree of understanding, integrity, and maturity of character in the care of the patient”